Learn About Alpha Mannosidosis

What is the definition of Alpha Mannosidosis?

Alpha-mannosidosis is a rare inherited disorder that causes problems in many organs and tissues of the body. Affected individuals may have intellectual disability, distinctive facial features, and skeletal abnormalities. Characteristic facial features can include a large head, prominent forehead, low hairline, rounded eyebrows, large ears, flattened bridge of the nose, protruding jaw, widely spaced teeth, overgrown gums, and large tongue. The skeletal abnormalities that can occur in this disorder include reduced bone density (osteopenia), thickening of the bones at the top of the skull (calvaria), deformations of the bones in the spine (vertebrae), knock knees, and deterioration of the bones and joints.

What are the causes of Alpha Mannosidosis?

Mutations in the MAN2B1 gene cause alpha-mannosidosis. This gene provides instructions for making the enzyme alpha-mannosidase. This enzyme works in the lysosomes, which are compartments that digest and recycle materials in the cell. Within lysosomes, the enzyme helps break down complexes of sugar molecules (oligosaccharides) attached to certain proteins (glycoproteins). In particular, alpha-mannosidase helps break down oligosaccharides containing a sugar molecule called mannose.

How prevalent is Alpha Mannosidosis?

Alpha-mannosidosis is estimated to occur in approximately 1 in 500,000 people worldwide.

Is Alpha Mannosidosis an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Alpha Mannosidosis Local Doctors?
Elite in Alpha Mannosidosis
Elite in Alpha Mannosidosis
Lyon, FR 

Nathalie Guffon practices in Lyon, France. Ms. Guffon is rated as an Elite expert by MediFind in the treatment of Alpha Mannosidosis. Her top areas of expertise are Alpha Mannosidosis, Acid Sphingomyelinase Deficiency (ASMD), Mucopolysaccharidoses (MPS), and Niemann-Pick Disease.

Elite in Alpha Mannosidosis
Elite in Alpha Mannosidosis
Cordoba, AN, ES 

Mercedes Campos-Gil practices in Cordoba, Spain. Ms. Campos-Gil is rated as an Elite expert by MediFind in the treatment of Alpha Mannosidosis. Her top areas of expertise are Alpha Mannosidosis, Congenital Hyperinsulinism, Obesity in Children, Obesity, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Alpha Mannosidosis
Elite in Alpha Mannosidosis
Hamburg, HH, DE 

Nicole Muschol practices in Hamburg, Germany. Ms. Muschol is rated as an Elite expert by MediFind in the treatment of Alpha Mannosidosis. Her top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), Alpha Mannosidosis, Osteotomy, and Bone Marrow Transplant.

What are the latest Alpha Mannosidosis Clinical Trials?
Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells

Summary: The primary objective of the study is to determine the safety and feasibility of intrathecal administration of DUOC-01 as an adjunctive therapy in patients with inborn errors of metabolism who have evidence of early demyelinating disease in the central nervous system (CNS) who are undergoing standard treatment with unrelated umbilical cord blood transplantation (UCBT). The secondary objective of t...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Who are the sources who wrote this article ?

Published Date: May 01, 2014
Published By: National Institutes of Health